Histiocytic sarcoma in renal transplant patients: a literature review.
Histiocytic sarcoma
Immune suppression
Kidney
Lymphoproliferative disorder
Renal transplant
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
03 Oct 2023
03 Oct 2023
Historique:
received:
09
06
2023
accepted:
24
08
2023
medline:
4
10
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Histiocytic sarcoma (HS) is defined as neoplasm resembling morphological and immunophenotypic characteristics of mature histiocytes. It is a rare form of lymphoid neoplasms. Despite advances in treatment and diagnosis of histiocytic sarcoma, majority of cases had poor prognosis due to progressive nature of the disease. In the following article, all reported cases of histiocytic sarcoma in renal transplant patients are reviewed. In our literature review, all relevant reports were collected electronically by entering the necessary keywords. A Boolean approach using Medical Subject Heading (MeSH) keywords was implemented. After establishing the inclusion/exclusion criteria, article titles and abstracts were evaluated by Systematic Reviews and Meta-Analyses (PRISMA) standards for 2020. All cases of histiocytic sarcoma in renal transplant patients were included. Based on our inclusion and exclusion criteria 4 case reports were yielded in this review. Two were males and 2 were females with the mean age of 42.25 years. Fever was the most common symptom. Although tumor originated from the native kidney on one patient, the site of the primary tumor was thorax, oropharynx, and transplanted kidney in the rest. Metastasis was detected in all cases. Prednisone was used for all cases. EBV was positive in 2 cases and negative in one of them. Histology was diagnostic and similar in all cases. Immunohistochemistry was done for 3 cases. Although chemotherapy was done for 3 patients, all 4 cases ended in mortality. Despite the fact that neoplasms are post renal transplant complications, histiocytic sarcoma is a scarce and fatal entity in such patients. Histological and immunohistochemistry tests are the corner stone in diagnosis of histiocytic sarcoma.
Sections du résumé
BACKGROUND
BACKGROUND
Histiocytic sarcoma (HS) is defined as neoplasm resembling morphological and immunophenotypic characteristics of mature histiocytes. It is a rare form of lymphoid neoplasms. Despite advances in treatment and diagnosis of histiocytic sarcoma, majority of cases had poor prognosis due to progressive nature of the disease. In the following article, all reported cases of histiocytic sarcoma in renal transplant patients are reviewed.
METHODS
METHODS
In our literature review, all relevant reports were collected electronically by entering the necessary keywords. A Boolean approach using Medical Subject Heading (MeSH) keywords was implemented. After establishing the inclusion/exclusion criteria, article titles and abstracts were evaluated by Systematic Reviews and Meta-Analyses (PRISMA) standards for 2020. All cases of histiocytic sarcoma in renal transplant patients were included.
RESULT
RESULTS
Based on our inclusion and exclusion criteria 4 case reports were yielded in this review. Two were males and 2 were females with the mean age of 42.25 years. Fever was the most common symptom. Although tumor originated from the native kidney on one patient, the site of the primary tumor was thorax, oropharynx, and transplanted kidney in the rest. Metastasis was detected in all cases. Prednisone was used for all cases. EBV was positive in 2 cases and negative in one of them. Histology was diagnostic and similar in all cases. Immunohistochemistry was done for 3 cases. Although chemotherapy was done for 3 patients, all 4 cases ended in mortality.
CONCLUSION
CONCLUSIONS
Despite the fact that neoplasms are post renal transplant complications, histiocytic sarcoma is a scarce and fatal entity in such patients. Histological and immunohistochemistry tests are the corner stone in diagnosis of histiocytic sarcoma.
Identifiants
pubmed: 37784161
doi: 10.1186/s13256-023-04140-4
pii: 10.1186/s13256-023-04140-4
pmc: PMC10546704
doi:
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
416Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Takahashi E, Nakamura S. Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53(1):1–8.
doi: 10.3960/jslrt.53.1
pubmed: 23801128
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.
pubmed: 21171509
Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28(9):1133–44.
doi: 10.1097/01.pas.0000131541.95394.23
pubmed: 15316312
Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol. 2010;13(3):225–37.
doi: 10.2350/09-03-0622-OA.1
pubmed: 19642834
Yoshida C, Takeuchi M. Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry. Intern Med. 2008;47(3):165–9.
doi: 10.2169/internalmedicine.47.0386
pubmed: 18239326
Pollen M, El Jamal S, Lewin J, Manucha V. Histiocytic sarcoma in a kidney transplant patient: a case report and review of the literature. Case Rep Pathol. 2016;2016:3591050.
pubmed: 27795864
pmcid: 5066022
Ventura Aguiar P, Dias C, Azevedo P, Silva HN, Almeida M, Pedroso S, et al. Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. J Nephropathol. 2015;4(3):97–100.
pubmed: 26312238
pmcid: 4544561
Tomlin J, Orosco RK, Boles S, Tipps A, Wang HY, Husseman J, et al. Successful treatment of multifocal histiocytic sarcoma occurring after renal transplantation with cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) followed by allogeneic hematopoietic stem cell transplantation. Case Rep Hematol. 2015;2015: 728260.
pubmed: 26167311
pmcid: 4475737
Kramer P, Prins ME, Kapsenberg JG, Bornkamm GW, Bijnen AB, Rohol PJ, et al. Persistent Epstein-Barr virus infection and a histiocytic sarcoma in a renal transplant recipient. Cancer. 1985;55(3):503–9.
doi: 10.1002/1097-0142(19850201)55:3<503::AID-CNCR2820550305>3.0.CO;2-2
pubmed: 2981149
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
doi: 10.1186/s13643-021-01626-4
pubmed: 33781348
pmcid: 8008539
Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10(3):136–45.
pubmed: 9238621
Penn I. Development of cancer as a complication of clinical transplantation. Transplant Proc. 1977;9(1):1121–7.
pubmed: 325738
Penn I. Tumors in allograft recipients. N Engl J Med. 1979;301(7):385.
doi: 10.1056/NEJM197908163010716
pubmed: 379644
Penn I. Malignant lymphomas in organ transplant recipients. Transplant Proc. 1981;13(1 Pt 2):736–8.
pubmed: 7022943
Tumour viruses. Lancet. 1982;1(8267):317–8.
Purtilo DT. Viruses, tumours, and immune deficiency. Lancet. 1982;1(8273):684.
pubmed: 6121992
Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41(1):1–29.
doi: 10.1046/j.1365-2559.2002.01418.x
pubmed: 12121233
Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4(1):87–93.
doi: 10.1046/j.1600-6135.2003.00274.x
pubmed: 14678038
Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–30.
doi: 10.1046/j.1600-6143.2003.00325.x
pubmed: 14974943
Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122(5):794–801.
doi: 10.1309/QHD6YFN81KQXUUH6
pubmed: 15491976
Wang E, Hutchinson CB, Huang Q, Sebastian S, Rehder C, Kanaly A, et al. Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a ‘transdifferentiation’ during the clonal evolution. Leuk Lymphoma. 2010;51(5):802–12.
doi: 10.3109/10428191003699845
pubmed: 20331331
Akiba J, Harada H, Kawahara A, Arakawa F, Mihashi H, Mihashi R, et al. Histiocytic sarcoma of the parotid gland region. Pathol Int. 2011;61(6):373–6.
doi: 10.1111/j.1440-1827.2011.02671.x
pubmed: 21615614
Harasen GL, Simko E. Histiocytic sarcoma of the stifle in a dog with cranial cruciate ligament failure and TPLO treatment. Vet Comp Orthop Traumatol. 2008;21(4):375–7.
doi: 10.3415/VCOT-07-05-0054
pubmed: 18704246
Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433–9.
doi: 10.1182/blood-2007-11-124792
pubmed: 18272816
pmcid: 2424145
Hibberd AD, Trevillian PR, Wlodarczyk JH, Kemp DG, Stein AM, Gillies AH, et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. Transplantation. 2013;95(1):122–7.
doi: 10.1097/TP.0b013e3182782f59
pubmed: 23238532
Sprangers B, Riella LV, Dierickx D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review. Am J Kidney Dis. 2021;78(2):272–81.
doi: 10.1053/j.ajkd.2021.01.015
pubmed: 33774079
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342(8886–8887):1514–6.
doi: 10.1016/S0140-6736(05)80084-4
pubmed: 7902900
van Leeuwen MT, Grulich AE, Webster AC, McCredie MR, Stewart JH, McDonald SP, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood. 2009;114(3):630–7.
doi: 10.1182/blood-2009-02-202507
pubmed: 19443660
Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation. 1999;68(8):1203–5.
doi: 10.1097/00007890-199910270-00024
pubmed: 10551653
Navarro MD, Lopez-Andreu M, Rodriguez-Benot A, Aguera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008;40(9):2936–40.
doi: 10.1016/j.transproceed.2008.09.025
pubmed: 19010153
Ferreiro JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, et al. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016;16(2):414–25.
doi: 10.1111/ajt.13558
pubmed: 26780579
Courville EL, Yohe S, Chou D, Nardi V, Lazaryan A, Thakral B, et al. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol. 2016;29(10):1200–11.
doi: 10.1038/modpathol.2016.130
pubmed: 27443517
Marcelis L, Tousseyn T. The tumor microenvironment in post-transplant lymphoproliferative disorders. Cancer Microenviron. 2019;12(1):3–16.
doi: 10.1007/s12307-018-00219-5
pubmed: 30680693
pmcid: 6529504